

# LIFE SCIENCE TREND ANALYSIS

GERMANY | 2024



VENTURE VALUATION  
GLOBAL VALUATION SERVICES



BIO DEUTSCHLAND

AUGUST 2024



# ABOUT US



The following statistical information has been obtained from Biotechgate, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

[www.biotechgate.com](http://www.biotechgate.com)



The German Biotech Database is a part of the global Biotechgate and is brought to you in partnership with BIO Deutschland, BIO.NRW, BioRN, and GTAI Germany Trade & Invest/HEALTH MADE IN GERMANY.

[www.germanbiotech.com](http://www.germanbiotech.com)




Biotechgate is owned and operated by Venture Valuation AG, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.

[www.venturevaluation.com](http://www.venturevaluation.com)

# OVERVIEW OF THE LIFE SCIENCE INDUSTRY


## NUMBER OF COMPANIES BY SECTOR



For the definition of categories please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Biotech Companies include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. Percentage value is expressed as % of total number of companies. Information displayed may alter as new information is received continuously



# OVERVIEW OF BIOTECH COMPANIES

## NUMBER OF COMPANIES BY SECTOR




# OVERVIEW OF OTHER LIFE SCIENCE RELATED COMPANIES

NUMBER OF COMPANIES BY OTHER LIFE SCIENCE RELATED SECTORS



# BIOTECH - THERAPEUTICS COMPANIES BY KEY ACTIVITIES


AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - THERAPEUTICS COMPANIES



For 269 Biotech Therapeutics companies there were 423 subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech – Therapeutics and Diagnostics subsectors as the percentage of the total number of Biotech – Therapeutics and Diagnostics subsectors with exclusion of the category Others. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Information displayed may alter as new information is received continuously.

# MEDICAL TECHNOLOGY COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF MEDICAL TECHNOLOGY COMPANIES




For 575 Medical Technology companies there were 1221 subsectors (key activity areas) assigned (one medtech company can be active in multiple areas). The graph displays Medical Technology subsectors as the percentage of the total number of Medical Technology subsectors with exclusion of categories with percentages lower than 3% and Others. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Information displayed may alter as new information is received continuously.


# BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE

BREAKDOWN BY INDICATION



BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech – Therapeutics and Diagnostics companies (excl. of Pharma or Biotech – Others or Biotech R&D Services companies). Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category. Information displayed in the chart may alter as new information is received continuously

# ASSETS AVAILABLE FOR OUT-LICENSING


## NUMBER OF ASSETS

### BY ASSET CLASS



■ Therapeutics ■ Diagnostics ■ Medical Devices ■ Technologies

### THERAPEUTICS IN DEVELOPMENT BY DEVELOPMENT PHASE




■ Preclinical ■ Phase I ■ Phase II ■ Phase III

The graph titled Therapeutics in Development by Development Phase displays a subset of the asset class Therapeutics. Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category.

# OVERVIEW OF OWNERSHIP


## PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR



For the definition of categories please visit [www.biotechgate.com/web/cms/index.php/covered\\_industry\\_sectors.html](http://www.biotechgate.com/web/cms/index.php/covered_industry_sectors.html). Percentage value is expressed as % of total number of companies in the sector. Information displayed may alter as new information is received continuously.

# COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2013-2022




The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2023 were excluded** since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.


# VENTURE FINANCING OF LIFE SCIENCE COMPANIES

## PRIVATE EQUITY ROUNDS | 2022-2023

### LIFE SCIENCE COMPANIES




### BIOTECH COMPANIES



Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# BIOTECH VENTURE FINANCING






## PRIVATE EQUITY ROUNDS – 5 YEAR REPORT



Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others. Financing data only includes private equity rounds (excl. private placements in public companies) of biotech companies (incl. therapeutic and diagnostic, R&D services and others). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# MAJOR BIOTECH VENTURE FINANCING ROUNDS (2023)

## TOP 5 PRIVATE EQUITY FINANCING ROUNDS | 2023

Company	Sector	Type of Round	USD M
Traceless Materials 	Biotech - Other	Series A	\$39
AMSilk 	Biotech – Other	Series C	\$27
Ariceum Therapeutics 	Biotech – Therapeutics	Series A	\$25
AaviGen 	Biotech - Therapeutics	Series B	\$19
Bluu 	Biotech - Other	Series A	\$17

The table shows the five biggest private equity financing rounds (excl. IPOs, research grants, loans) of private and independent biotech companies in 2023. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

# ABOUT BIOTECHGATE



**Biotechgate** is a leading **business development and licensing database** for the entire life science industry, offering a wealth of information on over 64,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 36,000 **licensing deals** and a **clinical trials database** containing over 920,000 records from registries around the world.

To register for a free trial access or to learn more about the different subscription options, please visit [www.biotechgate.com](http://www.biotechgate.com).

# OUR PARTNERS



[BioRN](#) is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany's strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders. The vision of BioRN is to develop the region into a world leading life science cluster attracting international investments and top global talent.

BioRN has more than 140 institutional members, including the top academic and research institutions, 10 global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups.

Biotechgate/Venture Valuation provide the [Guide to the Region Rhine-Main-Neckar](#) available at the BioRN website.

# OUR PARTNERS

## BIO DEUTSCHLAND

As the sector association of the biotechnology industry with more than 370 corporate members, [BIO Deutschland](#) has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. BIO Deutschland is Germany's biotechnology sector representative at the BDI, the Federation of German Industries, and at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way.

Venture Valuation/Biotechgate provides the [online directory](#) of BIO Deutschland member companies.

# OUR PARTNERS



[BIO.NRW](#) is the official network for Biotechnology and Life Science in North Rhine-Westphalia (NRW), Germany's largest and economically most powerful federal state. Since 2008, BIO.NRW acts on behalf of the State Government of NRW and the office is run by the Juelich Research Center. With its key thematic fields, BIO.NRW.red and BIO.NRW.eco, the network is a catalyst for the sustainable development of NRW's strengths in biotechnology and the bioeconomy. BIO.NRW stimulates cooperation between companies, research institutes, and the state sector along value-added chains– hereby setting a focus on the support of start-ups and SMEs with regard to financing, internationalization and access to public funding, i.e. project consortia.

Thanks to the partnership with Venture Valuation, BIO.NRW provides [free database](#) of clear and comprehensive information about life science and biotechnology companies from North Rhine-Westphalia. The information includes company profiles, contact details and a summary of products, services and technologies.

# OUR PARTNERS



[HEALTH MADE IN GERMANY](#) is the export initiative for the German healthcare industry implemented by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany, on behalf of the German Federal Ministry for Economic Affairs and Climate Action (BMWK).

HEALTH MADE IN GERMANY partnered with Venture Valuation/Biotechgate to create an [online company directory](#) that gives free access to 3500 profiles of companies active in the German healthcare market. The individual company profiles provide detailed information about each company's activities, product and services range, financial data and contact information. This allows to establish direct contact with potential partners in Germany.

# BIOTECHGATE DIGITAL PARTNERING

Virtual business development & licensing event  
Aug 26 – 30, 2024



[www.digitalpartnering.com](http://www.digitalpartnering.com)

# TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at [www.biotechgate.com](http://www.biotechgate.com). The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as [www.biotechgate.com](http://www.biotechgate.com) is clearly cited as the source. For all other uses please contact us for terms and conditions.



## BIOTECHGATE

*c/o Venture Valuation VV AG*

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



[www.venturevaluation.com](http://www.venturevaluation.com)